Apellis Pharmaceuticals, Inc. bolstered its chances of success for its intravitreal pegcetacoplan in geographic atrophy with Phase III follow-up data that vindicated a study previously viewed as a failure.
Apellis said on 16 March that in longer-term data from the Phase III DERBY and OAKS studies, pegcetacoplan had continued...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?